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Abstract
Objective: The objective of this selective EBM review is to determine whether or not “Does
Fecal Microbiota Transplantation cause Clinical Remission in Patients with Ulcerative Colitis?”
Study Design: Review of three English language primary studies published in 2015.
Data Sources: Two randomized control trials and a cohort study determining if fecal microbiota
transplantation does lead to clinical remission of Ulcerative Colitis were found by using PubMed
and Cochrane databases.
Outcome(s) Measured: The outcomes measured in all three studies were patient oriented
evidence that matters which is clinical remission. The outcomes in the Moayyedi et al. was
measured by the Mayo Score The Rossen et al. study determined clinical remission as SCCAI
score ≤ 2 in combination with ≥1 point improvement on the combined Mayo endoscopic score
of the sigmoid and rectum, compared to the baseline sigmoidoscopy, 12 weeks after the first
treatment. The Wei et al. trail determined clinical remission was defined as IBDQ >170 and
Mayo score <2 in Ulcerative Colitis.
Results: This review compares two randomized, double blind, placebo controlled clinical trials
and one cohort study in which the Moayyedi et al. and Wei et al. trial proved that Fecal
microbiota transplantation is effective in providing clinical remission in patients with active
Ulcerative Colitis; however, the Rossen et al. trial showed there was no significant statistical
difference between the experimental [FMT-D] and the placebo [FMT-A] group in inducing
clinical remission in patients with active Ulcerative Colitis.
Conclusions: Fecal Microbiota Transplantation does seem to provide effective treatment in
causing clinical remission of Ulcerative Colitis overall according to the three studies in this
review.
Key Words: fecal microbiota, Ulcerative Colitis
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INTRODUCTION
Ulcerative Colitis results from an abnormal response by the body’s immune system. The
immune system normally contains proteins and cells that protect the body from infection;
however, in Ulcerative Colitis, the immune system mistakes food, bacteria, and other material in
the intestine as foreign or infectious substances.1 This immune system impairment leads to a
chronic disease of the colon in which the mucosal lining of the colon becomes inflamed, leading
to diffuse friability and erosions which result with open sores or ulcers producing pus, mucus,
and bleeding.2 Patients with ulcerative colitis usually present with bloody diarrhea. Bowel
movements are frequent and small in volume as a result of rectal inflammation. Some other
associated symptoms include colicky abdominal pain, urgency, tenesmus, and incontinence.
Patients with mainly distal disease may have constipation accompanied by frequent discharge of
blood and mucus.3 Although considerable progress has been made in IBD research, investigators
do not yet know what causes this disease.
Ulcerative colitis affects 907,000 people in the United States, and is currently on the rise
with 38,000 new cases each year.4 Men and Women are equally likely to be affected, with most
diagnosed in their mid-30s.4 However, Ulcerative Colitis can occur at any age and recent studies
showed older men are more likely to be diagnosed than older women.4 The annual direct cost
based on US insurance claims data from 2003-2004 is $5,066 per patient, indirect costs were
$5,228 per patient, and the annual financial burden of IBD in the US may be more than $31
billion.4
Currently there is no definitive cure for Ulcerative Colitis but there are medications
currently out to provide symptomatic relief to treat the disease. The initial therapy for a patient
with Ulcerative Colitis is patient education; eat regular diet but limit intake of caffeine and gas-
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producing vegetables. Anti-diarrheal agents should not be given in the acute phase of the illness
but are safe and helpful in patients with mild chronic symptoms. For symptomatic relief,
medications are taken such as oral 5-ASA agents such as mesalamine, balsalazide, or
sulfasalazine. If no improvement is seen on 5-ASA after 4-8 weeks of improvement then add on
corticosteroids such as prednisone or methylprednisolone. Patients not responding to 5-ASA or
corticosteroids or for corticosteroid-dependent patients give immunomodulators such as
Mercaptopurine or azathiopurine or an Anti- TNF like Infliximab. If all these medications don’t
work then last resort is surgery to remove the diseased portion of the colon.2
In Ulcerative Colitis the composition of the microbiota is different in that of a healthy
individual in that the diversity is lower and contains lower number of Clostridium clusters and
Bacteriodes. It is unclear if this disturbed microbiota is the cause or result of UC.5 Fecal
microbiota transplantation may offer a method of enriching the gut microbiota leading to
remission of Ulcerative Colitis.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not fecal microbiota
transplantation cause clinical remission in patients with Ulcerative Colitis.

METHODS
These three studies, two randomized controlled trials and one cohort study, this
systematic review was based on the population age, the intervention, and the outcomes
measured. The populations of the research article were all adults, both males and females, ages
18-70 year old, diagnosed with active or established Ulcerative Colitis. The common
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intervention among all studies was transplantation of fecal microbiota. The demographics and
characteristics of each study are displayed in Table 1. For the study by Moayeddi et al, the
comparison groups were patients with Ulcerative Colitis given Fecal Microbiota Transplantation
(FMT) from healthy donor versus Patient given a placebo.6 Patients were randomized in this
study to either receive 50 mL of FMT or a placebo of 50 mL of water given as a retention enema
once per week for a total of 6 weeks. On the seventh week, patients returned to complete the
final Mayo Clinic Score, Inflammatory Bowel Disease Questionnaire (IBDQ) and an exit
sigmoidoscopy to compare to the baseline scores.6 In the Wei et al study, there was no
comparison study and just measured the results of patients receiving FMT over a 4 week period.
The way this transplantation procedure took place was the participants were maintained on 500
mg of vancomycin twice a day, for three consecutive days 12 hours before the Fecal Microbiota
Transplantation (FMT). On the day before the procedure participants also took polyethylene
glycol to wash out any fecal material and then the 300 mL donor material was administered by a
colonoscopy’s biopsy channel.7 In the Rossen et al study, the comparison groups were patients
with Ulcerative Colitis, were randomized either receiving 2 duodenal infusions of donor feces
from healthy host [FMT-D] or 2 duodenal infusions of autologous feces [FMT-A] which served
as a control in participants receiving their own feces. This was administered via nasoduodenal
tube. Prior to the administration, patients were pretreated with bowel lavage the evening and
morning before the treatment to washout much of the particpants indigenous microbiota.5 Three
weeks later the same procedure was repeated and the outcomes were measured at week 12. The
outcome in these 3 studies, which were important, was Clinical Remission that qualifies as
patient oriented evidence that matters (POEM).
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Keywords used in the searches were “fecal microbiota and Ulcerative Colitis.” All
articles were published in peer-reviewed journals in the English language. The articles were
searched through the Cochrane databases and through PubMed. The articles were patient
oriented evidence that matters (POEM). Inclusion criteria for this study is randomized control
trials and cohort studies based on patient oriented evidence that matters, patients aged 18 or older
with active Ulcerative Colitis defined as Mayo Clinic The exclusion criteria for this study are
patients under the age of 18, articles that were not randomized double blind, articles without
placebo controlled trails, and disease oriented trials. The statistics reported in this study were pvalues, Relative Benefit Increase (RBI), Absolute Benefit Increase(ABI), number needed to treat
(NNT).
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Table 1: Demographics & Characteristics of included studies
Study

Type

#pts

Age
(yrs)

Inclusion Criteria

Exclusion Criteria

w/d

Intervention

Moayyed
iP
(2015)

Randomi
zed
Controll
ed
Study
(RCT)

75

18-60

-Eligible Patients were 18
years or older with active
Ulcerative Colitis defined as
Mayo Clinic Score 4 with an
endoscopic Mayo Clinic
Score 1.
- Concomitant treatment for
UC, such as mesalamine,
glucocorticoids,
immunosuppressive therapy,
or tumor necrosis factor
antagonists were permitted,
provided these had been used
for at least 12 weeks( 4 weeks
for glucocorticoids) and
disease remained active.
- 5 patients who were
previously exposed to
mesalamine or steroids had a
30 day washout period before
being enrolled.

Pt taken antibiotics or probiotics in
last 30 days, had concomitant C
difficile infection or another enteric
pathogen, had a disease severity that
required hospitalization, were
pregnant, or were unable to give
informed consent.

5

Fecal
Microbiota
Transplantation
by Healthy
Donor
(Retention
Enema
Approach)

Wei Y
(2015)

Cohort
Study

11

24-70

-Age Range 18-70y/o
-CDAI Score of 150 and 400;
or Mayo score(UCDAI) of 210.

-Pregnant
- End-Stage Disease
- If pts participating in other trials
within 3 months prior to
transplantation.
If infectious colitis
- Pt scheduled for abdominal surgery
- If pt took
probiotics/prebiotics/synbiotics/antib
iotic/PPI orally in the last month
- If pt suffer from severe anemia,
heart cerebrovascular accident, and
bypass or underwent stent
implantation last 6 months
- If pt has coagulation disorders or
immune suppression status or
underwent abdominal transplant last
3 months.
- If pt took TNF monoclonal
antibody 2 months before
transplantation or planned to take it
within one month after
transplantation.
- If pt had history of megacolon.

1

Fecal
transplantation
from healthy
donors (via
colonoscopy
biopsy channel
in UC cases)

Rossen

Randomi
zed
Controll
ed
Study
(RCT)

50

30-56

- Established Ulcerative
Colitis according to the
Leonard Jones Criteria, a pt
reported SCCAI of ≥4 and
≤11 and stable medication,
which was continued during
the study period.
- Subjects allowed stable
doses of thiopurines,
mesalamine, or
corticosteroids ≤ 10mg/d for
8 weeks before inclusion.
- An endoscopic score ≥1 at
baseline sigmoidoscopy was
mandatory for inclusion.

- Pt excluded if used anti-tumor
necrosis factor or methtroxate
treatment within 8 weeks before
inclusion, or cyclosporine within 4
weeks before inclusion.
- An infectious cause of a Ulcerative
Colitis disease flare
- Hx of colonectomy, a current
stoma, life expectancy <12 months,
pregnancy, and hospital admission
were exlusion criteria.
- Pts were not allowed to use
antibiotics or probiotics within 6
weeks before inclusion.

2

- Fecal
Microbiota
Transplantation
from Healthy
Donors.
- 2 Duodenal
Infusions of a
suspension of
Donor Feces
[FMT-D] vs. 2
Duodenal
Infusions of a
suspension of
Autologous
Feces [FMT-A]

(2015)
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Outcomes Measured
The outcomes measured in all three studies were patient oriented evidence that matters which is
clinical remission. The outcomes in the Moayyedi et al. was measured by the Mayo Score which
is a composite of subscores from four categories, including stool frequency, rectal bleeding,
findings of flexible proctosigmoidoscopy or colonoscopy, and physician’s global assessment,
with a total score ranging from 0–12. Within the endoscopic component of the Mayo Score, a
score of 0 is given for normal mucosa or inactive UC, while a score of 1 is given for mild disease
with evidence of mild friability, reduced vascular pattern, and mucosal erythema. A score of 2 is
indicative of moderate disease with friability, erosions, complete loss of vascular pattern, and
significant erythema, and a score of 3 indicates ulceration and spontaneous bleeding. Mucosal
healing has been defined as a Mayo endoscopic sub score of 0 or 1 in major trials of biological
therapies in UC.6 The Moayyedi et al. study determined clinical remission which is defined as
full Mayo Score <3 and an endoscopic Mayo Clinic Score=0.6 The Rossen et al. study
determined clinical remission as SCCAI score ≤ 2 in combination with ≥1 point improvement
on the combined Mayo endoscopic score of the sigmoid and rectum, compared to the baseline
sigmoidoscopy, 12 weeks after the first treatment.5 The Wei et al. trail determined clinical
remission was defined as IBDQ >170 and Mayo score <2 in Ulcerative Colitis.7
Results
The Moayyedi et al study was a randomized double blind control study with outcomes
that were dichotomous data and based on intent to treat. To begin this study there were 85
patients who were assessed and eligible for the trial. Ten patients from the study were soon
dropped due to 7 subjects no longer having active disease, 2 for being clostridum dificilepositive and 1 withdrew before randomization. So 75 patients were left to be randomized into the
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placebo group and other half allocated to the FMT trail. 37 patients were in the placebo group
and 38 patients were in the FMT experimental group. Patients were randomized in this study to
either receive 50 mL of FMT or a placebo of 50 mL of water given as a retention enema once per
week for a total of 6 weeks and on the 7th week final Mayo Clinic score, Inflammatory Bowel
disease questionnaire (IBDQ) and an exit sigmoidoscopy to compare to the baseline scores. 3
people dropped out from the placebo group and 2 from the FMT experimental group leading to
70 patients completing the study; 34 completing the placebo trial and 36 completing FMT
experimental trail. The outcomes were measured for clinical remission at the seventh week after
treatment. At the of 7 weeks, the clinical remission of Ulcerative Colitis showed a significant
difference in adequate relief between the placebo group and fecal microbiota transplantation
experimental group. The proportion of participants in the FMT group that had clinical remission
was 23.7% whereas 5.4% of the placebo group had clinical remission (Table 2). With p-value of
.03 is statistically significant there is clinical remission of Ulcerative Colitis given FMT
compared to placebo.6
Table 2: Percent of Participants with Clinical Remission of Ulcerative Colitis 6 weeks after Treatment
# of Participants in Group
Fecal Microbiota
Transplantation [FMT]
Placebo

38

# of participants with
Clinical Remission
9

% of participants with
Clinical Remission
23.7%

37

2

5.4%

This data from above in Table 2 shows the control event rate [CER] is 5.4%. On the other hand,
the experiment event rate [EER], which included the FMT GROUP, is 23.7%. From this data the
numbers needed to treat was 6, so for every 6 patients administered Fecal Microbiota
Transplantation, one more patient will have remission of Ulcerative Colitis compared to the
placebo at 7 weeks.
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The Rossen et al. study was a randomized double blind control study with dichotomous
data and based on intention to treat. In the Rossen et al. study, 50 patients were randomized into
the experimental and control groups and received 2-duoudenal infusions of donor feces from
healthy host [FMT-D] or 2-duodenal infusions autologous feces [FMT-A], which is the placebo.
Only 48 patients completed the study; 23 in the FMT-D and 25 in the FMT-A group. The
infusions were administered at week 0 and week 3 and the outcomes were recorded at the end of
12 weeks from the SCCAI score and combined Mayo endoscopic score. The proportion of
participants from the experimental group [FMT-D] group that had clinical remission was 30.4%
whereas the proportion of the placebo group [FMT-A] that had clinical remission was 20%. So
based on the p-value of .51 data did not show a statistical significant difference in the clinical
remission between the placebo and experimental group.5
Table 3: Percent of Participants with Clinical Remission of Ulcerative Colitis 12 weeks after treatment
# of Participants in Group
FMT-D
FMT-A

23
25

# of participants with
Clinical Remission
7
5

% of participants with
Clinical Remission
30.4%
20%

The data from above shows that the control event rate [CER], which involved the FMT-A
group is 20%. On the other hand, the experimental event rate [EER], which is the FMT-D group
is 30.4%. The numbers needed to treat is 10, so for every 10 patients administered fecal
microbiota transplantation from healthy donor one more patient will have remission of
Ulcerative Colitis compared to FMT-A group at the end of 12 weeks.
In the Wei et al. study, which was a cohort study with outcomes was presented as
continuous data but was able to be converted into dichotomous data. In this study there were 11
patients with Ulcerative Colitis that were treated with FMT via colonoscopy or nasojejuanal tube
infusion. At the end of 4 weeks Inflammatory Bowel Disease Questionnaire, which measured
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quality of life, and Mayo score was calculated and compared to the baseline. There was no
control study.7
Table 4: Results based on Mean Change 4 weeks after Fecal Microbiota Transplantation

IBDQ Score
Mayo Score

Baseline Score

4 week after treatment Score

135.50
5.80

177.30
1.50

Based on the table above the mean Mayo score in Ulcerative Colitis patients decreased
significantly from baseline score of 5.80 to 1.50 which shows dramatic decrease in Mayo Score
<2. With a p-value <.01, it provides statistical significance that there is clinical remission of
Ulcerative Colitis 4 weeks post treatment. Also, the IBDQ score rose significantly in patients
from baseline starting from 135.50 to 177.30 with end IBDQ score >170. With a p-value of
0.00063, it provides statistical evidence that there is Clinical Remission of Ulcerative Colitis 4
weeks post treatment.
Discussion
Ulcerative Colitis is a chronic disease of the colon in which the mucosal lining of the
colon becomes inflamed which can lead to open sores or ulcers producing pus, mucus, and
bleeding.2 Currently there is no definitive cure for Ulcerative Colitis but there are medications
currently out to provide symptomatic relief to treat the disease. In Ulcerative Colitis the
composition of the microbiota is different in that of a healthy individual in that the diversity is
lower and contains lower number of Clostridium clusters and Bacteriodes.5 So it is ambiguous if
this disturbed microbiota is the cause of UC. Fecal microbiota transplantation enriching the gut
microbiota leading to remission of Ulcerative Colitis.5
This review compares two randomized, double blind, placebo controlled clinical trials
and one cohort study in which the Moayyedi et al. and Wei et al. trial proved that Fecal
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microbiota transplantation is effective in providing clinical remission in patients with active
Ulcerative Colitis; however, the Rossen et al. trial showed there was no significant statistical
difference between the experimental [FMT-D] and the placebo [FMT-A] group in inducing
clinical remission in patients with active Ulcerative Colitis.
These three articles did contain some limitations in this review. In the Moayeedi et al.
study, the donor stool was not held as a control as patients either received as frozen or fresh fecal
sample. Seemed as if frozen stool seemed to be a bit more effective but may be confounded due
to frozen stool being from Donor B. Patients who received Donor B stool seemed to be most
effective so not all donor stools effective in treating UC because each stool made of differing
microbiota. So another way to keep a better control was all patients received fecal sample from
same host to prevent any variables. Another limitation was not performing colonoscopy at study
exit and it is possible that patients with extensive colitis have active disease beyond the limit of
the flexible sigmoidoscope. Another limitation was a small sample size.6 Some limitations in the
Rossen et al. study is small sample size. Another limitation is inconsistent dosages of fecal
transplants every 3 weeks. Another limitation in this particular study is making sure all fecal
matter is composed of similar microbiota to make sure treatment is specific-to-specific
microbiota, which might yield data on selecting beneficial groups for donation instead of whole
microbiome transplantation.5 The limitations in the Wei et al. trials are small sample size as well
as not having a control.7
Conclusion
Fecal Microbiota Transplantation does seem to provide effective treatment in causing
clinical remission of Ulcerative Colitis overall according to the three studies in this review.
Further study is needed to really evaluate the long term effects with the treatment of Fecal
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microbiota transplation and to see if it is sustainable in providing long term favorable results.
Further studies should include larger sample size, controlled donor feces with similar microbiota,
controlled route of administration either colonoscopy or retention enema approach, and should
focus on the effect of FMT on clinical remission for periods longer than 4-7 weeks and follow up
with patient long term for at least 5 years.
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